Lymphoma

First-line therapy with axicabtagene ciloleucel induced objective responses in 89% of patients with high-risk large B-cell lymphoma, according to phase 2 study results.

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine.

Most patients with cancer demonstrated antibody responses to COVID-19 vaccination after two doses of the mRNA-1273 vaccine, according to an observational study published in JAMA Oncology.

The expansion of Medicaid under the Affordable Care Act correlated with an increase in 2-year OS rates among patients newly diagnosed with cancer, according to study results published in JNCI: Journal of the National Cancer Institute.

Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.

Tisagenlecleucel may be less toxic than axicabtagene ciloleucel for patients with relapsed or refractory follicular lymphoma, study results suggested.

Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line therapy than standard treatment for relapsed or refractory large B-cell lymphoma, according to study results.

The addition of utomilumab after infusion with axicabtagene ciloleucel induced a 75% response rate among adults with relapsed or refractory large B-cell lymphoma, data from the ZUMA-11 trial showed.

More than half of patients treated with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease responded to therapy, phase 3 study results showed.

SALT LAKE CITY — Zanubrutinib improved outcomes compared with bendamustine/rituximab among adults with treatment-naive deletion 17p-negative chronic lymphocytic leukemia or small lymphocytic lymphoma, according to phase 3 study results.